# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

# Washington, D.C. 20549

# **SCHEDULE 13G**

## (Amendment No. \_\_)\*

## **Under the Securities Exchange Act of 1934**

<u>Ultragenyx Pharmaceutical Inc.</u> (Name of Issuer)

Common Stock, par value \$0.001 per share (Titles of Class of Securities)

90400D108

(CUSIP Number)

December 31, 2014

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

O Rule 13d-1(b) O Rule 13d-1(c) ⊠ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out of a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "<u>Act</u>") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the *Notes*).

CUSIP 90400D108				13G	Page 2 of 9			
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) TPG Group Holdings (SBS) Advisors, Inc.							
2	CHECK THE APPROPRIATE BOX IF A			MEMBER OF A GROUP	(a) o (b) o			
3	SEC USE ONLY							
4	CITIZENSHIP OR	PLACE (	OF ORGANIZA	TION				
	Delaware							
	Beluware	5	SOLE VOTI	NG POWER				
		5	- 0 -					
	NUMBER OF SHARES BENEFICIALLY	6		DTING POWER				
	OWNED BY EACH		1,596,420	POSITIVE POWER				
	REPORTING PERSON	7	- 0 -					
	WITH:	8	SHARED DI	SPOSITIVE POWER				
			1,596,420					
9	AGGREGATE AN	MOUNT	BENEFICIALL	Y OWNED BY EACH REPORTING PEF	SON			
	1,596,420							
10	CHECK BOX IF T	HE AGG	REGATE AMO	UNT IN ROW (9) EXCLUDES CERTAIN	N SHARES o			
11	PERCENT OF CL	LASS REI	PRESENTED B	Y AMOUNT IN ROW 9				
	4.6% (1)							
12	TYPE OF REPORTING PERSON							
	СО							

(1) Based on a total of 34,846,472 shares of Common Stock (as defined below) of the Issuer (as defined below) outstanding as of February 5, 2015 as reported in the prospectus supplement filed by the Issuer with the Securities and Exchange Commission (the "Commission") on February 5, 2015.

	CUSIP No. 90400D108			13G	Page 3 of 9			
	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) David Bonderman							
			ATE BOX IF A M	IEMBER OF A GROUP				
2		-	-		(a) o (b) o			
3	SEC USE ONLY							
1	CITIZENSHIP OR PLACE OF ORGANIZATION							
•	United States							
	United States		SOLE VOTIN	G POWFR				
		5						
	NUMBER OF		- 0 -					
	SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON	6	SHARED VO	TING POWER				
			1,596,420					
		7		OSITIVE POWER				
		/						
			- 0 -					
	WITH:	8	SHARED DIS	POSITIVE POWER				
			1,596,420					
9	AGGREGATE A	MOUNT		OWNED BY EACH REPORTING PERSON				
,								
	1,596,420							
10	CHECK BOX IF T	HE AGG	REGATE AMOU	INT IN ROW (9) EXCLUDES CERTAIN SHA	ARES o			
	PERCENT OF CI	LASS RE	PRESENTED BY	AMOUNT IN ROW 9				
11								
	4.6% (2)	ית אורי	TRON					
12	TYPE OF REPORTING PERSON							
	IN							

(2) Based on a total of 34,846,472 shares of Common Stock of the Issuer outstanding as of February 5, 2015 as reported in the prospectus supplement filed by the Issuer with the Commission on February 5, 2015.

CUSIP No. 90400D108				13	G		Page 4 of 9	
1	NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY) James G. Coulter							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o (b) o							
3	SEC USE ONLY							
4 CITIZENSHIP OR PLACE OF ORGANIZATION United States								
E	NUMBER OF SHARES EENEFICIALLY OWNED BY EACH	5 6 7	1,596,420	NG POWER DTING POWER POSITIVE POWER				
	REPORTING		- 0 -					

	PERSON WITH:	8 SHARED DISPOSITIVE POWER 1,596,420	
9	AGGREGATE A	MOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON	
	1,596,420		
10	CHECK BOX IF T	HE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES o	
11	PERCENT OF C	LASS REPRESENTED BY AMOUNT IN ROW 9	
	4.6% (3)		
12	TYPE OF REPOR	TING PERSON	
	IN		

(3) Based on a total of 34,846,472 shares of Common Stock of the Issuer outstanding as of February 5, 2015 as reported in the prospectus supplement filed by the Issuer with the Commission on February 5, 2015.

#### Item 1(a). Name of Issuer:

Ultragenyx Pharmaceutical Inc. (the "Issuer")

# Item 1(b). Address of Issuer's Principal Executive Offices:

60 Leveroni Court Novato, California 94949

## Item 2(a). Name of Person Filing:

This Schedule 13G is being filed jointly by TPG Group Holdings (SBS) Advisors, Inc., a Delaware corporation ("<u>Group Advisors</u>"), David Bonderman and James G. Coulter (each, a "<u>Reporting Person</u>" and, together, the "<u>Reporting Persons</u>"), pursuant to an Agreement of Joint Filing incorporated by reference herein in accordance with Rule 13d-1(k)(1) under the Act.

Group Advisors is the general partner of TPG Group Holdings (SBS), L.P., a Delaware limited partnership, which is the sole member of TPG Holdings I-A, LLC, a Delaware limited liability company, which is the general partner of TPG Holdings I, L.P., a Delaware limited partnership, which is the sole member of TPG Biotechnology GenPar III Advisors, LLC, a Delaware limited liability company, which is the general partner of TPG Biotechnology GenPar III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology GenPar III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology GenPar III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology CenPar III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners III, L.P., a Delaware limited partnership, which is the general partner of TPG Biotechnology Partners III, L.P., a Delaware limited partnership ("<u>TPG Biotech III</u>"), which directly holds 1,596,420 shares of Common Stock of the Issuer (the "<u>Shares</u>") reported herein. Because of Group Advisors' relationship to TPG Biotech III, Group Advisors may be deemed to beneficially own the Shares directly held by TPG Biotech III.

David Bonderman and James G. Coulter are officers and sole shareholders of Group Advisors, and may therefore be deemed to beneficially own the Shares held by TPG Biotech III. Messrs. Bonderman and Coulter disclaim beneficial ownership of the Shares except to the extent of their pecuniary interest therein.

## Item 2(b). Address of Principal Business Office or, if none, Residence:

The principal business address of each of the Reporting Persons is as follows:

c/o TPG Global, LLC 301 Commerce Street, Suite 3300 Fort Worth, Texas 76102

## Item 2(c). Citizenship:

See response to Item 4 of each of the cover pages.

## Item 2(d). Titles of Classes of Securities:

Common Stock, par value \$0.001 per share.

## Item 2(e). CUSIP Number:

90400D108

Page 5 of 9

Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a(n):							
	(a)		Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78o).				
	(b)		Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).				
	(c)		Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).				
	(d)		Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).				
	(e)		Investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).				
	(f)		Employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).				
	(g)		Parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).				
	(h)		Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (13 U.S.C. 1813).				
	(i)		Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).				
	(j)		Non-U.S. institution, in accordance with § 240.13d-1(b)(1)(ii)(J).				
	(k)		Group in accordance with §240.13d-1(b)(1)(ii)(K).				
	If filing as a non-U.S. institution in accordance with §240. 13d-1(b)(1)(ii)(J), please specify the type of institution:						

Page 6 of 9

#### Item 4. Ownership

## (a) **Amount beneficially owned:**

See responses to Item 9 on each cover page.

#### (b) **Percent of class:**

See responses to Item 11 on each cover page.

(c) Number of shares as to which such person has:

## (i) Sole power to vote or to direct the vote:

See responses to Item 5 on each cover page.

## (ii) Shared power to vote or to direct the vote:

See responses to Item 6 on each cover page.

## (iii) Sole power to dispose or to direct the disposition of:

See responses to Item 7 on each cover page.

#### (iv) Shared power to dispose or to direct the disposition of:

See responses to Item 8 on each cover page.

#### Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\boxtimes$ .

#### Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

# Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

See response to Item 2(a) above.

# Item 8. Identification and Classification of Members of the Group.

Not Applicable.

## Item 9. Notice of Dissolution of Group.

Not Applicable.

# Item 10. Certification.

Not Applicable.

Page 7 of 9

#### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 13, 2015

TPG Group Holdings (SBS) Advisors, Inc.

By: <u>/s/ Ronald Cami</u> Name: Ronald Cami Title: Vice President

David Bonderman

By: <u>/s/ Ronald Cami</u> Name: Ronald Cami, on behalf of David Bonderman (4)

James G. Coulter

By: <u>/s/ Ronald Cami</u> Name: Ronald Cami, on behalf of James G. Coulter (5)

Page 8 of 9

<sup>(4)</sup> Ronald Cami is signing on behalf of Mr. Bonderman pursuant to an authorization and designation letter dated July 1, 2013, which was previously filed with the Commission as an exhibit to a Schedule 13D filed by Mr. Bonderman on August 14, 2013 (SEC File No. 005-83906).

<sup>(5)</sup> Ronald Cami is signing on behalf of Mr. Coulter pursuant to an authorization and designation letter dated July 1, 2013, which was previously filed with the Commission as an exhibit to a Schedule 13D filed by Mr. Coulter on August 14, 2013 (SEC File No. 005-83906).

#### Exhibit Index

Exhibit 1

Agreement of Joint Filing as required by Rule 13d-1(k)(1) under the Act.\*

Page 9 of 9

<sup>\*</sup> Incorporated herein by reference to the Agreement of Joint Filing by TPG Advisors II, Inc., TPG Advisors III, Inc., TPG Advisors V, Inc., TPG Advisors V, Inc., TPG Advisors V, Inc., TPG Advisors VI, Inc., T3 Advisors, Inc., T3 Advisors, Inc., T9G Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter, dated as of February 14, 2011, which was previously filed with the Commission as Exhibit 1 to Schedule 13G filed by TPG Group Holdings (SBS) Advisors, Inc., David Bonderman and James G. Coulter on February 14, 2011.